

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”

Madam,

We read with interest the recently published review article by Patel *et al.* titled “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.”^[1] Tanezumab is under investigation for the treatment of osteoarthritis pain and chronic low back pain by Pfizer Inc. and Eli Lilly & Company. As Pfizer or Lilly were not involved or consulted regarding the content of this article, we would like to point out that the molecular formula of tanezumab presented in Figure 1 is incorrect. For a more accurate representation of the structure of tanezumab, we refer readers to an article by La Porte *et al.*^[2]

—On behalf of the tanezumab development team.

Financial support and sponsorship

Editorial support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and was funded by Eli Lilly & Co and Pfizer.

Conflicts of interest

Leslie Tive is a full-time employee of, and own stock and/or stock options in, Pfizer Inc. David Shelton is a consultant for, and owns stock in, Pfizer Inc. Lars Viktrup is a full-time employee of, and owns stock and/or stock options in, Eli Lilly & Company.

Leslie A. Tive, Lars Viktrup¹, David Shelton²

Global Medical Affairs, Pfizer Inc., New York, NY, ¹Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, ²Formerly of Pfizer Global Research and Development (Rinat), Pfizer Inc., South San Francisco, California, USA

Address for correspondence: Dr. Leslie A. Tive, Pfizer Inc., 235 E 42nd St, New York, NY, 10017, USA.
E-mail: leslie.tive@pfizer.com

References

1. Patel MK, Kaye AD, Urman RD. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. *J Anaesthesiol Clin Pharmacol* 2018;34:111-6.
2. La Porte SL, Eigenbrot C, Ultsch M, Ho WH, Foletti D, Forgie A, *et al.* Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized fab-antigen complexes. *MABs* 2014;6:1059-68.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code:	Website: www.joacp.org
	DOI: 10.4103/joacp.JOACP_155_18

How to cite this article: Tive LA, Viktrup L, Shelton D. Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”. *J Anaesthesiol Clin Pharmacol* 2018;34:548.

© 2019 Journal of Anaesthesiology Clinical Pharmacology | Published by Wolters Kluwer - Medknow